<?xml version="1.0" encoding="UTF-8"?>
<p id="par0045">A total of 278 consecutive respiratory samples (nasal and nasopharyngeal swabs) collected for COVID-19 diagnosis between 20 February and 24 March 2020 were included in the study; twenty additional nasopharyngeal swabs from patients known to be positive for other Human Coronaviruses were used to establish clinical specificity of the Simplexa™ COVID-19 Direct assay. Moreover, to evaluate the performance of the test in a different clinical specimen, a total of 33 Broncho-Alveolar Lavage (BAL) collected for COVID-19 diagnosis between 20 March and 03 April 2020 were also analysed in parallel with the Simplexa™ COVID-19 Direct assay and the routine laboratory method, based on the WHO protocols [
 <xref rid="bib0035" ref-type="bibr">7</xref>,
 <xref rid="bib0040" ref-type="bibr">8</xref>], using the Abbot 
 <italic>m</italic>2000 extraction platform.
</p>
